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descriptive scores and distribution. No floor/ceiling effect (defined as 
more than 15% of respondents having respectively the lowest/highest 
score) was found except for the 'PSA anxiety' subscale (floor effect, 
72% of respondents). The Cronbach's α coefficients were high (α ≥ 0.70 
good internal consistency) for total score (α = 0.80), 'PCa anxiety' (α = 
0.87) and 'fear of recurrence' (α = 0.77) subscales. Internal consistency 
was lower for 'PSA anxiety' subscale (α = 0.62). The means of item to 
total correlation coefficients were: 0.63 (range 0.45-0.76) for 'PCa 
anxiety', 0.36 (range 0.2-0.46) for 'PSA anxiety' and 0.68 (range 0.65-
0.75) for 'fear of recurrence' (scores below 0.75 suggest deleting the 
item).  
 
  
Conclusions: The 'PCa anxiety' and the 'fear of recurrence' subscales 
showed strong internal consistency and reliability. The reliability of 
'PSA anxiety' subscale was rather weak, as observed in the original 
version of the MAX-PC. Recruitment of RT pts is ongoing. Further 
analyses will include reliability of the questionnaire over time (test 
re-test correlations), factor analyses and test validation to 
discriminate PCa specific related anxiety in an Italian population.  
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Purpose/Objective: We aimed to assess the dosimetric impact of 
advanced delivery RT techniques, including volumetric modulated arc 
therapy (VMAT), intensity modulated RT (IMRT), and intensity 
modulated proton beam RT (IMPT) in high-risk prostate cancer 
patients with sentinel nodes (SN) in the pararectal region. 
Materials and Methods: Plans for VMAT, IMRT and IMPT were 
optimized for 6 of such patients. The prescribed dose was 50.4 Gy to 
the prostate, seminal vesicles, and the pelvic lymph nodes including 
the pararectal SN (PTV2). This was followed by a boost dose of 28 Gy 
to the prostate and seminal vesicles (PTV1). IMRT and IMPT were 
delivered with 7 and 3 beams respectively and VMAT with 2 arcs. Plans 
aimed to cover at least 95% of the planning target volume with 95% of 
the prescribed dose. Results were assessed by comparing Dose-Volume 
Histograms and NTCP between the three treatment modalities. 
Results: Target coverage (PTV1 and PTV2) was improved with IMPT 
when compared to VMAT and IMRT, while coverage of the SN was 
improved with VMAT (D1Gy 67.91±7.5) when compared with IMRT 
(D1Gy 70.08±5.0). The percentages of rectal, bladder, bowel, and 
femoral head volumes were significantly decreased with IMPT when 
compared to VMAT and IMRT. The comparison between VMAT (D1Gy 
50.70±4.1 and D50Gy 33.52±2.5) and IMRT (D1Gy 51.89±3.4 and D50Gy 
36.55±2.2) showed a significant improvement only for the left femoral 
head irradiation, likely due to the IMRT fields spatial distribution. The 
NTCP evaluation using the relative seriality model showed a 
significant improvement for bladder (contracture and volume loss) and 
rectum (bleeding) ≥ grade-3 late toxicity with IMPT (mean±SD, 0.0±0.0 
and 0.4±0.0) when compared with IMRT (mean±SD, 1.4±1.1 and 
4.6±3.3), respectively.  
Conclusions: When compared to 7 beam IMRT, VMAT treatment plans 
showed an improved tumor coverage of the pararectal SN and may be 
considered an optimal solution with X-ray beams. IMPT showed further 
sparing potential of the organs at risk and more favorable NTCP scores 
especially for bladder contraction and volume loss as well as for rectal 
bleeding.  
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Purpose/Objective: The dose distribution has been improved with the 
advance of intensity-modulated radiation therapy (IMRT), the high-
dose treatment has been possible and the adverse event has been 
decreased. According to this evidence, the position as a radical 
treatment option for the prostate cancers in Japan has been 
established. So we expect similar advantages of IMRT, instead of the 
conventional radiation, with an ethical approval of our hospital, a 
total of 20 patients with PSA failure postoperative prostate cancer 
have been treated with IMRT. We herein review and discuss about 
them. 
Materials and Methods: Between April 2003 and Jun 2012, a total of 
20 patients have been treated with IMRT because of PSA failure after 
the radical prostatectomy for prostate cancer. The background of the 
patients is as bellow: the median age was 67years old (52-83), the 
median T stage was T3a (T1c-T3b), the median initial PSA was 
9.9ng/ml (4.15-71), the median Gleason score was 8 (6–10), positive 
surgical margin cases were in 7(35%), the median post operative PSA 
nadir was 0.0475ng/ml (0.003-2.26), and the median PSA before IMRT 
was 0.478ng/ml (0. 001 - 4.15). The body of the patient was fixed 
with Stereotactic Body Frame one hour after urination, and the 
treatment planning CT image was taken and the clinical target volume 
was created according to preoperative CT/MRI images. The part of the 
irradiation was prostate bed only in 4 and prostate bed and lymph 
node in 16. IMRT was performed by 10MV photon from 7 directions. 
The median total irradiation dose was 67.5Gy (66-70). And, the 
median lymph nodes dose was 54Gy (51-57) in a simultaneous boost 
method on target. Combined hormone therapies were 10cases. 
Results: The biochemical non-recurrence rate was 65% after IMRT in 
2-73 months (median; 12.5months) follow-up period. The interval time 
of the biological recurrence after irradiation was 6-73 months 
(median; 18months). Genitourinary toxicities were 6 cases, 
gastrointestinal toxicities were 11 cases and the other was 1 case. 
They were all acute events with Grade 1 in the Common Terminology 
Criteria for Adverse Events v. 4.0 definitions. There is no late adverse 
event. 
Conclusions: IMRT for PSA failure after radical prostatectomy for 
prostate cancer is considered to be effective and safety. For being 
established that it will be as a salvage option for failure cases of 
postoperative prostate cancer, we have to accumulate more cases and 
observe them with long-term follow-up. 
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Purpose/Objective: Surgery is the most common treatment for 
endometrial cancer. It is the reference for precise FIGO staging and 
gives more information on histological prognostic factors (tumor 
extension, grade, myometrium invasion, and involved lymph nodes). 
No one questions the diagnostic value of lymphadenectomy, however 
therapeutic benefit is still an open debate. The aim of this study is to 
evaluate the results of adjuvant radiotherapy in women who suffered 
from endometrial cancer and were treated by hysterectomy with or 
without lymphadenectomy.  
Materials and Methods: Between 2002 and 2009, 97 women with 
histologically proven endometrial cancer were treated in our 
department by adjuvant radiotherapy after hysterectomy with or 
without lymphadenectomy. 
Results: The range of age was 31-80 years (median, 58.1 years). 83 
patients (85.5%) were postmenopausal, 18 patients suffered from 
coexisting comorbidities (18 hypertension, 12 diabetes). Obesity, a 
family history cancer and nulliparity were respectively observed in 
(23, 16, and 20 women). The histopathological diagnosis was obtained 
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by endometrial curetting in 51 patients (52.5%). 94 patients 
underwent surgery (a total abdominal hysterectomy plus bilateral 
salpingo-oopherectomy in 75.5%, simple hysterectomy in 21.6%) with 
lymphadenectomy in only 25 cases. They were classified according to 
FIGO stage on: 61 stage I (12: IA, 7: IB, 42: IC), 13:IIB, 21: III (08 IIIA, 3 
IIIB, 10 IIIC) and 2 IVa. Myometrial invasion was > 50% in 78 % of cases. 
Type I endometrial carcinoma represent the most common type (93 
patients), with histological grade (G); 64% G1, 18.5% G2; 13.5 G3. All 
patients received radiation therapy; (external beam radiotherapy and 
brachytherapy). After median follow up of 49.9 months (2- 120 
months) loco-regional recurrence occurred in 8 patients (8.3%) and 
metastasis in 12 patients (12.3%), the 5-year overall survival rate was 
83 %. There was statistically significant overall survival between stage 
I-II and III-IV p=0.001), however there was no significant overall 
survival between surgery with or without lymphadenectomy (88%, 
87%, p = 0.89), others prognostic factors affecting the overall survival 
were analyzed: comorbidities (without vs. with: 85% vs. 83%), 
hormonal status (pre vs.postmenopausal: 86% vs. 83%), histological 
type (1 vs. 2: 86% vs. 73%), grade (1,2,3) respectively (81%,71%, 40%), 
and the depth of myometrial invasion (<50 vs. > 50%: 94% vs 81%).  
Conclusions: Radiotherapy is a highly effective adjuvant treatment 
providing an excellent loco-regional control rate; pelvic 
lymphadenectomy does not offer clear therapeutic benefit in the 
treatment of endometrial cancer, considering morbidity for 
lymphadenectomy, the technique of sentinel lymph nodes biopsy can 
potentially establish an alternative for staging. Combined therapeutic 
modalities (surgery, radiotherapy, chemotherapy, and targeted 
therapy) can improve survival and prognosis for high-risk endometrial 
cancer. 
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Purpose/Objective: The use of brachytherapy (BT) combined with 
external beam radiotherapy (EBRT), is an essential part of cervical 
cancer radiotherapy treatment and also has an important role in 
developing radiotherapy complications afterwards. During the last 
decade, concepts for three-dimensional image-based treatment 
planning in BT have been developed and that brought closer BT and 
EBRT in terms of technical development. This preliminary study is 
aimed at showing our first clinical results and a dosimetric comparison 
for organs at risk (OAR) using X-ray and CT/MR based BT planning. 
Materials and Methods: Implementation of image–based 
brachytherapy in our Institute was started in November 2008 and till 
June 2009 six patients with advanced cervical cancer were treated 
with this BT planning approach, using PLATO planning system on CT or 
CT/MR fused images. In the beginning of 2012 we started using 
Oncentra as our main planning system and after a transition period, 
results for 2 patients (4 applications) were included. The overall 
treatment approach consisted of pelvic EBRT, concomitant with BT 
and concurrent weekly administration of Cisplatin chemotherapy. All 
patients underwent X-ray 2D based planning, at 3 patients CT, at 3 
patients CT/MR PLATO planning was done at first BT application, and 
for 2 patients (4 applications) MR Oncentra based planning was done 
at first and third BT application, with tandem and two ovoids and TD 
of 7Gy/A. Delineation of rectum, bladder, sigmoid colon and high-risk 
CTV was done according to guidelines by Viswanathan et al and GEC-
ESTRO. The maximum dose to rectum and bladder (Rmax and Bmax), 
based on ICRU recommendation, calculated by X-ray imaging and dose 
to 0,1cm3, 1cm3 and 2cm3, for the bladder, rectum and sigma 
calculated from DVHs were compared. The volume of HR-CTV and 
values of D100, D90 and V100 were also calculated. 
Results: The median dose of EBRT at the time of first BT was 19Gy 
(14-28Gy). HR-CTV mean volume value was 47.54 ± 23.04 cm3 and 
dose parameters D90 6.31± 1.72Gy; D100 3.99 ± 1.43Gy; V100 80.38 ± 
14.48%. Mean dose values for rectum were: Rmax 5,3 ± 2,1Gy, 
D0,1cm3 7,6 ± 2,7Gy, D1cm3 6.0 ± 1,8Gy and D2cm3 5,4 ± 1,5Gy. There 
was statistically significant difference in dose at Rmax and D0,1cm3 
with higher dose obtained at D0,1cm3 and no statistically significant 
difference at the doses of D1cm3 and D2 cm3. Mean dose values for 
bladder were: Bmax 4,4 ± 1,7Gy, D0,1cm3 7.2 ±1.7Gy, D1cm3 5.7 ± 
1.1Gy and D2cm3 55.2 ±1.0Gy and statistically significant higher dose 
was obtained at D0,1cm3 and D1cm3 compared to Bmax. Doses to 
sigmoid colon at D0,1cm3 6.6± 1.9Gy, D1cm3 5.4 ± 1,5Gy and D2cm3 4.9 
± 1,3Gy were found. 
Conclusions: Larger tumor sizes led to inadequate HR-CTV coverage 
with desired BT dose. As expected, mean values of estimated rectum 
and bladder D0.1cm3 volume-dose parameters obtained by 3D BT 
planning, showed higher values compared to those obtained with 2D 
X-ray planning approach. Also, additional information about dose 
values to sigmoid colon was revealed with 3D planning. Further 
investigation in needed in order to fully implement 3D BT in our 
institution and perhaps change our present concomitant EBRT/BT 
treatment approach. 
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Purpose/Objective: To investigate the acute toxicity of 3D conformal 
EBRT with concurrent chemotherapy keeping Dmax around 105% in 
carcinoma cervix patients.  
Materials and Methods: Carcinoma cervix patients stage IIAto IIIB (n = 
22) treated during November 2011 to November 2012 at the institution 
with 3D conformal chemo-radiation were included. They received 
weekly cisplatin 40mg/m2. They received 46 Gy /23 fractions 5 
fractions per week while ensuring that the PTV maximum dose (Dmax) 
is around 105%. EBRT was followed by two fractions of intracavitary 
brachytherapy 9 Gy each. Normally the prescribed dose is normalized 
to the isodose curve that covers at least 99% of PTV which usually 
results in a higher PTV Dmax. (around 110%).In this study the coverage 
of 99% of PTV by the prescribed dose is ensured while maintaining the 
PTV Dmax around 105% and thus better dose homogeneity. This is 
achieved by optimization methods like using subfields, adjusting 
weightages,using mixed beam energies etc. The purpose of the study 
is to analyze how this reflects on the acute RTOG toxicity profile of 
the patient during EBRT. This is a type of dose optimization where an 
IMRT like plan can be generated using conventional 3D CRT despite 
the process being time consuming as the results are expected to be 
better than a conventional 3D CRT plan.  
Results:  
All the 22 patients completed EBRT. The analysis is given below: 
· Age: between 30-55 years (median 45) 
· Stageof disease - IIB (72.72%) and IIIB (27.27%) 
· Numberof cycles of chemotherapy received – 5 cycles (63.63%), 4 
cycles (27.27%) and 3cycles (9.09%). 
· Tumorsize: <4cm (18.18%) and >4cm (81.81%) 
· Performance status: ECOG 1 (77.27%) and ECOG 2 (22.72%) 
· TOXICITY ASSESSMENT: ( RTOG gradewise in percentages ) 
 
Toxicity in % Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Skin 50 40.9 9.09 0 0 
Vaginal Mucosa 81.81 18.18 0 0 0 
Rectum 50 36.36 13.63 0 0 
Diarrhoea 45.45 81.2 13.63 9.09 0  
Vomitting 63.63 13.63 13.63 9.09 0 
Small bowel 35.29 35.29 11.76 17.6 0 
Large Bowel 47.05 41.17 11.76 0 0 
Neutropenia 72.72 22.72 0 4.5 0 
Anemia 9545 0 0 454 0 
Thrompcytopenia 90.9 4.5 4.54 0 0 
 
Conclusions: The predominant toxicity was small bowel toxicity 
followed by hematological toxicity. 3D conformal concurrent chemo 
radiation with Dmax around 105% reduces acute RTOG toxicity 
particularly grade 3 and 4, results in better dose homogeneity and 
improves patient compliance for radiotherapy.  
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Purpose/Objective: To report the experience with FDG PET/CT 
guided-Tomotherapy and simultaneous integrated boost dose 
escalation (SIB) as a substitute for brachytherapy or to increase the 
dose to the FDG PET positive lymph nodes. 
Materials and Methods: From 08/2006 -05/2012 40 gynecologic cancer 
pts received pelvic/pelvic-lombo-aortic FDG PET/CT Guided 
